- Nadel, S., et al., Drotrecogin alfa (activated) in children with severe sepsis: a
multicentre phase III randomised controlled trial. Lancet, 2007. 369(9564): p. - 836 Woodward, B. and M. Car-43.^ twright, Safety of drotrecogin alfa (activated) in severe
sepsis: data from adult clinical trials and observational studies. J Crit Care, 2009.
24(4): p. 595-602. - Deans, K.J., et al., Practice misalignments in randomized controlled trials:
Identificati 444 - 50. on, impact, and potential solutions. Anesth Analg, 2010. 111(2): p. - Deans, K.J., et al., Defining the standard of care in randomized controlled trials of
titrated therapies. Curr Opin Crit Care, 2004. 10(6): p. 579-82. - Minneci, P.C., et al., The importance of usual care control groups for safety
monitoring and validity during critical care research. Intensive Care Med, 2008. 34(5): p. 942-7. - Rey, C., et al., Intervention to reduce catheter-related bloodstream infections in a
pediatric intensive care unit. Intensive Care Med, 2011. 37(4): p. 678-85. - Deans, K.J., et al., The relevance of practice misalignments to trials in
- transfusion medicine. Vox Sang, 2010. 99(1): p. 16Deans, K.J., et al., Randomization in clinical trials of-23. titrated therapies:^
unintended consequences of using fixed treatment protocols. Crit Care Med,
2007. 35(6): p. 1509-16. - Finfer, S., et al., Intensive versus conventional glucose control in critically ill
- patients. N Engl J Med, 2009. 360(13): p. 1283Hebert, P.C., et al., A multicenter, randomized, controlled clinical trial of -97.^
transfusion requirements in critical care. Transfusion Requirements in Critical
Care Investigators, Canadian Critical Care Trials Group. N Engl J Med, 1999.
340(6): p. 40 9 - 17. - van den Berghe, G., et al., Intensive insulin therapy in critically ill patients. N Engl
- J Med, 2001. 345(19): p. 1359Wiener, R.S., D.C. Wiener, and R.J. Larson, Benefits and risks of tight glucose -67.^
control in critically ill adults: a meta-analysis. JAMA, 2008. 300(8): p. 933-44. - Deans, K.J., et al., Substantiating the concerns about recombinant human
activated protein C use in sepsis. Crit Care Med, 2004. 32(12): p. 2542-3. - Hicks, P. and D.J. Cooper, The Surviving Sepsis Campaign:guidelines for management of severe sepsis and septic shock: 2008. Crit Care International
Resusc, 2008. 10(1): p. 8. - Schultz, M.J., et al., The new Surviving Sepsis Campaign recommendations on
glucose control should be reconsidered. Intensive Care Med, 2008. 34(4): p. 779- - 80; author reply 781Dellinger, R.P., et al., Surviving Sepsis Campaign guidelines for management of -2.^
severe sepsis and septic shock. Crit Care Med, 2004. 32(3): p. 858-73. - Dellinger, R.P., et al., Surviving Sepsis Campaign guidelines for management of
severe sepsis and septic shock. Intensive Care Med, 2004. 30(4): p. 536-55. - Larson, E.L., D. Quiros, and S.X. Lin, Dissemination of the CDC's Hand Hygiene Guideline and impact on infection rates. Am J Infect Control, 2007. 35(10): p.
666 - 75.
marcin
(Marcin)
#1